High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells

Summary

The major complication of diabetes mellitus is accelerated atherosclerosis that entails an inflammatory process, in which fractalkine and monocyte chemotactic protein-1 (MCP-1) play a key role.We investigated the effect of diabetes-associated high glucose (HG) on these chemokines and signalling mechanisms involved in human aortic smooth muscle cells (SMC). Exposure of SMC to HG resulted in an increase of fractalkine and MCP-1 expression and the activated mitogen-activated protein kinase (MAPK) signalling pathway, a process associated with elevated oxidative stress.Transfection with decoy oligodeoxynucleotides identified the involvement of transcription factors activator protein 1 (AP-1) and nuclear factor kappa B (NF-κB) in the observed up-regulation of chemokines. The MAPK inhibitors blocked the phosphorylation of IkBα and c-jun, indicating the role of MAPK in NF-κB and AP-1 activation in SMC under HG conditions.The up-regulation of MCP-1 and fractalkine was associated with increased adhesive interactions between HG-exposed SMC and monocytes. Treatment of HG-exposed SMC with peroxisome proliferator-activated receptors α (PPAR α ) activators (fenofibrate and clofibrate) resulted in a reduction of mRNA and protein expression of MCP-1 and fractalkine.In conclusion, HG upregulates the expression of fractalkine and MCP-1 in SMC leading to increased monocyte-SMC adhesive interactions by a mechanism involving activation of MAPK, activator protein-1 (AP-1) and NF-κB. The increased expression of these two pro-inflammatory chemokines and the ensuing increased adhesion between SMC and monocytes may trigger the inflammatory process associated with further vascular complications of diabetes.

Keywords

Fractalkine - MCP-1 - high glucose - smooth muscle cells - MAPK signalling

• References

• 1 Combadiere C, Potteaux S, Gao JL. et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipo-protein E double knockout mice. Circulation 2003; 107: 1009-1016.
• 2 Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost 2007; 97: 730-737.
• 3 Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007; 97: 714-721.
• 4 Suzuki LA, Poot M, Gerrity RG. et al. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes 2001; 50: 851-860.
• 5 Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-358.
• 6 Lo IC, Shih JM, Jiang MJ. Reactive oxygen species and ERK 1/2 mediate monocyte chemotactic protein-1-stimulated smooth muscle cell migration. J Biomed Sci 2005; 12: 377-388.
• 7 Cipriani B, Borsellino G, Poccia F. et al. Activation of C-C beta-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 2000; 95: 39-47.
• 8 Chen YM, Chiang WC, Lin SL. et al. Dual regulation of tumor necrosis factor-alpha-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappaB and activator protein-1: modulation by type III phosphodiesterase inhibition. J Pharmacol Exp Ther 2004; 309: 978-986.
• 9 Bazan JF, Bacon KB, Hardiman G. et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
• 10 Umehara H, Bloom E, Okazaki T. et al. Fractalkine and vascular injury. Trends Immunol 2001; 22: 602-607.
• 11 Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340.
• 12 Lucas AD, Bursill C, Guzik TJ. et al. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003; 108: 2498-2504.
• 13 Dragomir E, Manduteanu I, Voinea M. et al. Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells. J Diabetes Complications 2004; 18: 289-299.
• 14 Hinokio Y, Suzuki S, Hirai M. et al. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia 1999; 42: 995-998.
• 15 Manduteanu I, Voinea M, Antohe F. et al. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol 2003; 477: 269-276.
• 16 Srinivasan S, Bolick DT, Hatley ME. et al. Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol Chem 2004; 279: 31930-31936.
• 17 Mohamed AK, Bierhaus A, Schiekofer S. et al. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999; 10: 157-167.
• 18 Tirziu D, Jinga VV, Serban G. et al. The effects of low density lipoproteins modified by incubation with chondroitin 6-sulfate on human aortic smooth muscle cells. Atherosclerosis 1999; 147: 155-166.
• 19 Weber C, Aepfelbacher M, Haag H. et al. Tumor necrosis factor induces enhanced responses to platelet-activating factor and differentiation in human monocytic Mono Mac 6 cells. Eur J Immunol 1993; 23: 852-859.
• 20 Maedler K, Storling J, Sturis J. et al. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/ Kir6.2) selective potassium channel opener in human islets. Diabetes 2004; 53: 1706-1713.
• 21 Takaishi H, Taniguchi T, Takahashi A. et al. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Commun 2003; 305: 122-128.
• 22 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
• 23 Ungvari Z, Csiszar A, Edwards JG. et al. Increased superoxide production in coronary arteries in hyper-homocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003; 23: 418-424.
• 24 von Hundelshausen P, Koenen RR, Sack M. et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
• 25 Fichtner-Feigl S, Fuss IJ, Preiss JC. et al. Treatment of murineTh1- andTh2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115: 3057-3071.
• 26 Sorescu D, Weiss D, Lassegue B. et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-1435.
• 27 Zalba G, San Jose G, Moreno MU. et al. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal 2005; 07: 1327-1336.
• 28 Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). Int J Mol Med 2002; 09: 85-89.
• 29 Dragomir E, Tircol M, Manduteanu I. et al. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 2006; 44: 440-449.
• 30 De Keulenaer GW, Ushio-Fukai M, Yin Q. et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant pro-tein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 385-391.
• 31 Jordan NJ, Watson ML, Williams RJ. et al. Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol 1997; 122: 749-757.
• 32 Braun M, Pietsch P, Schror K. et al. Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res 1999; 41: 395-401.
• 33 Zeiffer U, Schober A, Lietz M. et al. Neointimal smooth muscle cells display a proinflammatory pheno-type resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. Circ Res 2004; 94: 776-784.
• 34 Inoguchi T, Sonta T, Tsubouchi H. et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003; 14: S227-232.
• 35 Nakagami H, Kaneda Y, Ogihara T. et al. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev 2005; 01: 59-63.
• 36 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
• 37 Goebeler M, Kilian K, Gillitzer R. et al. The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endothelial cells. Blood 1999; 93: 857-865.
• 38 Sukkar MB, Issa R, Xie S. et al. Fractalkine/ CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1230-1234.
• 39 Chen S, Mukherjee S, Chakraborty C. et al. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol 2003; 284: C263-722.
• 40 Ramana KV, Friedrich B, Srivastava S. et al. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 2004; 53: 2910-2920.
• 41 Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995; 270: 16483-16486.
• 42 Kyriakis JM. Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Gene Expr 1999; 07: 217-231.
• 43 Saatian B, Zhao Y, He D. et al. Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem J 2006; 393: 657-668.
• 44 Zambon A, Gervois P, Pauletto P. et al. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 2006; 26: 977-986.
• 45 Delerive P, De Bosscher K, Besnard S. et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. The Journal of biological chemistry 1999; 274: 32048-32054.
• 46 Scott R, Best J, Forder P. et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005; 04: 13.